Central validation of HER2 status to determine heterogeneity of marker expression in HER2-positive gastric cancer (GC).

Ivonne Haffner(Leipzig University), Florian Lordick(Leipzig University), Miriam Ahlborn(Klinikum Braunschweig), S. Neumann(Fraunhofer Project Centre Wolfsburg), Christian Wittekind(University Hospital Leipzig), Jorge Riera‐Knorrenschild, Stefan Fuxius(Praxis für Hämatologie und Onkologie), Katrin Schierle(University Hospital Leipzig), Birgit Luber(Technical University of Munich), Beate Rau(Medizinische Hochschule Hannover), Ludwig Fischer von Weikersthal(Praxis für Hämatologie und Onkologie), Dieter Maier(Biomax Informatics (Germany)), Florian Weißinger(Evangelisches Krankenhaus Bielefeld), Albrecht Kretzschmar(Roche (Switzerland)), Thomas Decker
Journal of Clinical Oncology
February 1, 2017
10.1200/jco.2017.35.4_suppl.12
Cited by 0

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Gastric cancer
|The Lancet|2020|4.8k
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k